Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 15/20 | 0.62 |
| ▸ | JAK1 | P23458 | 5/20 | 0.62 |
| ▸ | JAK3 | P52333 | 8/20 | 0.59 |
| ▸ | PTK2 | Q05397 | 7/20 | 0.59 |
| ▸ | IKBKB | O14920 | 1/20 | 0.49 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | TYK2 | P29597 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7974882 | 0.88 | JAK2 (0.70) | JAK2JAK1JAK3PTK2IKBKB | |
| SCHEMBL7963216 | 0.83 | JAK2 (0.68) | JAK2JAK1JAK3PTK2IKBKB | |
| SCHEMBL13882579 | 0.83 | JAK2 (0.60) | JAK2JAK1JAK3PTK2IKBKB | |
| SCHEMBL13072781 | 0.82 | JAK2 (0.66) | JAK2JAK1JAK3PTK2IKBKB | |
| SCHEMBL13073195 | 0.81 | JAK2 (0.60) | JAK2JAK1JAK3PTK2IKBKB | |
| SCHEMBL3213852 | 0.80 | JAK2 (0.72) | JAK2JAK1JAK3PTK2IKBKB | |
| SCHEMBL7978007 | 0.80 | JAK2 (0.72) | JAK2JAK1JAK3PTK2IKBKB | |
| SCHEMBL3216073 | 0.79 | JAK2 (0.58) | JAK2JAK1JAK3PTK2TYK2 | |
| SCHEMBL7964541 | 0.79 | JAK2 (0.79) | JAK2JAK1JAK3PTK2IKBKB | |
| SCHEMBL13072789 | 0.78 | JAK2 (0.72) | JAK2JAK1JAK3PTK2IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298339-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298339-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | AXL, TYRO3, FLT3 | JAK2 16/4885JAK1 14/4885JAK3 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.